CytoSorbents (STU:HQE) Cyclically Adjusted Book per Share: €12.40 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HQE CytoSorbents Corp STU:HQE
45 GF Score
Price €5.92
GF Value €16.19
! 5 Warning Signs
View Full Analysis

What is CytoSorbents Cyclically Adjusted Book per Share?

CytoSorbents STU:HQE 45 Cyclically Adjusted Book per Share is €12.40 as of Jun. 2026. GuruFocus rates STU:HQE with a GF Score™ of 45/100 and a GF Value™ of €16.19. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CytoSorbents's adjusted book value per share for the three months ended in Jun. 2026 was €-0.208. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €12.40 for the trailing ten years ended in Jun. 2026.

During the past 12 months, CytoSorbents's average Cyclically Adjusted Book Growth Rate was -0.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 23.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 75.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of CytoSorbents was 168.70% per year. The lowest was -32.90% per year. And the median was 36.05% per year.

As of today (2026-09-11), CytoSorbents's current stock price is €5.92. CytoSorbents's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €12.40. CytoSorbents's Cyclically Adjusted PB Ratio of today is 0.48.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CytoSorbents was 1814.05. The lowest was 0.44. And the median was 7.52.


CytoSorbents  (STU:HQE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CytoSorbents's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.92/12.40
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CytoSorbents was 1814.05. The lowest was 0.44. And the median was 7.52.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CytoSorbents Cyclically Adjusted Book per Share Related Terms


CytoSorbents Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CytoSorbents's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoSorbents Cyclically Adjusted Book per Share Chart

CytoSorbents Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.82 6.13 10.54 13.54 12.23

CytoSorbents Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.31 11.85 12.23 12.42 12.40

STU:HQE vs LFWD, GTHP, PMI: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, CytoSorbents's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Cyclically Adjusted PB Ratio falls into.


STU:HQE
45GF Score
CytoSorbents Corp STU:HQE
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoSorbents Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoSorbents's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.208/333.9520*333.9520
=-0.208

Current CPI (Jun. 2026) = 333.9520.

CytoSorbents Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.960 241.428 1.328
201612 0.989 241.432 1.368
201703 -1.144 243.801 -1.567
201706 4.982 244.955 6.792
201709 5.555 246.819 7.516
201712 5.956 246.524 8.068
201803 7.780 249.554 10.411
201806 11.688 251.989 15.490
201809 10.818 252.439 14.311
201812 9.321 251.233 12.390
201903 8.202 254.202 10.775
201906 6.295 256.143 8.207
201909 3.753 256.759 4.881
201912 1.877 256.974 2.439
202003 10.622 258.115 13.743
202006 11.675 257.797 15.124
202009 31.391 260.280 40.276
202012 29.980 260.474 38.437
202103 29.852 264.877 37.637
202106 28.347 271.696 34.842
202109 27.469 274.310 33.441
202112 25.346 278.802 30.360
202203 23.023 287.504 26.743
202206 20.544 296.311 23.154
202209 18.027 296.808 20.283
202212 15.228 296.797 17.134
202303 12.276 301.836 13.582
202306 10.014 305.109 10.961
202309 7.768 307.789 8.428
202312 7.899 306.746 8.600
202403 6.383 312.332 6.825
202406 5.698 314.175 6.057
202409 4.276 315.301 4.529
202412 3.850 315.605 4.074
202503 4.303 319.799 4.493
202506 3.208 322.561 3.321
202509 2.447 324.800 2.516
202512 1.605 324.054 1.654
202603 0.605 330.213 0.612
202606 -0.208 333.952 -0.208

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €12.40 mean?
CytoSorbents (STU:HQE) has a Cyclically Adjusted Book per Share of €12.40 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CytoSorbents and its competitors.
Is CytoSorbents' Cyclically Adjusted Book per Share too high?
CytoSorbents' current Cyclically Adjusted Book per Share is €12.40. Overall, CytoSorbents has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' Cyclically Adjusted Book per Share compare to LFWD and GTHP?
CytoSorbents' Cyclically Adjusted Book per Share of €12.40 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CytoSorbents and its competitors. CytoSorbents's current Cyclically Adjusted Book per Share is €12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
CytoSorbents (STU:HQE) has a current Cyclically Adjusted Book per Share of €12.40. The stock's GF Value™ is €16.19, compared to a current price of €5.92 — trading 63.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is €12.40. CytoSorbents' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CytoSorbents (STU:HQE), the current Cyclically Adjusted Book per Share is €12.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytoSorbents (STU:HQE) Overvalued in 2026?

Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued. The current stock price of €5.92 is trading 63.4% below its estimated GF Value™ of €16.19.

Key valuation signals for STU:HQE:

  • Cyclically Adjusted Book per Share: €12.40
  • GF Value™: €16.19 vs. price of €5.92 (63.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:HQE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytoSorbents Business Description

Other Exchanges CTSO:USA
Address 305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
45GF Score

Get the complete analysis for STU:HQE

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.92
Price
€16.19
GF Value